Affimed N.V. (AFMD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individu ...

Affimed (NASDAQ:AFMD) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company’s shares to undergo a reverse split later today.AFMD stock will go through a one-for-10 reverse stock split after markets close today. That will result in the company’s shares starting to trade on a split-adjusted basis when markets open on Monday.Shareholders approved of this reverse stock split during the company’s on June 21, 2023. It’s also worth mentioning that this split won’t allow ...

I’m about to drop a truth bomb about speculative stocks under $1.Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana? You don’t wanna.” Subsequently, the crowd erupted in laughter but the officer got his point across. Yes, Tijuana is an exciting and vibrant city, no doubt about it. However, people – especially young underage college students – can get carried away.That’s the reality behind speculative stocks under $1. It’s like Tijuana, where the same restrictions ...

MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior approval of the Company's supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 ("Common Shares") per share. The reverse stock split is expected to be effected afte ...

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohortFollow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scanStudy to be expanded to a total of 40 EGFRwt NSCLC patientsEnrollment in the EGFR-mutant (mut) NSCLC cohort is ongoingData from both the EGFRwt and EGFRmut cohorts expected in H1 2024 MANNHEIM, Germa ...

MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines. Under the terms of the agreement, Ampersand Biomedicines will acquire AbCheck for a purchase price of $6 million, consisting of $5 million in cash to ...

Affimed N.V. (NASDAQ:AFMD) Q3 2023 Results Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Alexander Fudukidis - Director and Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Conference Call Participants Srikripa Devarakonda - Truist Securities Li Watsek - Cantor Fitzgerald Daina Graybosch - Leerink Partners Yanan Zhu - Wells Fargo Bradley Canino ...

HARNESSING THE UNTAPPED POTENTIAL OF THE INNATE IMMUNE SYSTEM FOR ONCOLOGY Q3 2023 Financial Results & Operational Progress NASDAQ: AFMD November 14, 2023 Forward-Looking Statements / Cautionary Note 2 This presentation and the accompanying oral commentary contain "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, including statements regarding our future ...

Affimed N.V. (NASDAQ:AFMD) Q2 2023 Earnings Call Transcript August 10, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Daina Graybosch - Leverink Partners Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Co Yana ...

Affimed N.V. (NASDAQ:AFMD) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Srikripa Devarakonda - Truist Securities Bradley Canino - Stifel Ya ...